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Abstract: Background: The intense efforts made during 3-week stage races may reduce iron
metabolism and hematological parameters. These efforts may increase the levels of circulating
muscle damage markers and some hormones. All of these physiological changes may have negative
consequences not only for the performance of athletes but also for their health. The main aim of
this study was to evaluate the effects of supplementation with 80 mg/day of iron on haematological
parameters, serum cortisol and biochemical muscle indicators on elite male cyclists during the 3-week
stage race the Vuelta a España. Our secondary aim was to examine whether the hematological profile
is associated with muscular damage parameters and cortisol. Methods: Eighteen elite male cyclists
from two teams were randomly assigned to one of two groups: (1) control group (CG, n = 9; age:
26.1 ± 4.6 years; maximum oxygen uptake per kg: 78.0 ± 5.4 mL/kg/min) or (2) group treated with
80 mg/day iron (800 mg of iron protein succinylate, ITG, n = 9; age: 25.7 ± 6.4 years; maximum oxygen
uptake per kg: 77.6 ± 6.5 mL/kg/min). The cyclists were subjected to blood tests one week before
the start of the race (T1) and after 4 weeks of treatment, coinciding with the end of the competition
(T2). Iron metabolism parameters, muscle damage indicators and serum cortisol were assessed.
Repeated-measures ANOVA with group as a factor (GC and ITG) were used to examine the differences
between groups throughout the study (time × group) after iron supplementation treatment. Results:
Significant differences were observed between groups throughout the study in the group-by-time
interaction and changes in serum iron (GC: −8.93 ± 10.35% vs. ITG: 0.60 ± 8.64%; p = 0.018), ferritin
(GC: −13.88 ± 23.53% vs. ITG: 91.08 ± 118.30%; p = 0.004), haemoglobin (GC: 10.00 ± 3.32% vs. ITG:
13.04 ± 5.64%; p < 0.001), haematocrit (GC: −1.17 ± 3.78% vs. ITG: 7.32 ± 3.92%; p < 0.001) and cortisol
(GC: 24.74 ± 25.84% vs. ITG: –13.54 ± 13.61%; p = 0.005). However, no significant group-by-time
interaction was observed for the circulating muscle biomarkers. Additionally, significant negative
correlations of serum iron, haemoglobin and haematocrit with muscle circulating biomarkers and
cortisol (p < 0.05) were observed. Conclusions: Oral iron supplementation with 80 mg/day iron
(800 mg of iron protein succinylate) effectively prevented a decline in haematological parameters
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(serum iron, ferritin, haemoglobin and haematocrit) and maintained optimal levels of recovery in
elite cyclists during the Vuelta a España. Moreover, the hematological values were shown to have
relationship with muscular recovery parameters.
Keywords: recovery; iron supplementation; exercise; cyclist; muscular biomarkers; performance
1. Introduction
Iron is an essential micronutrient that plays a significant role in physical performance, particularly
in demanding endurance sports, such as cycling [1–3]. Of special interest are long stage races in which
iron metabolism, hematological parameters, muscle enzymes and hormones undergo changes for
which impacts on cyclists’ health have not been assessed [1,4]. The intense and sustained efforts made
during 3-week stage races may reduce blood hemoglobin (Hb), ferritin (FER) and serum iron (sFe)
concentrations in endurance cyclists, resulting in marginal or deficient iron states, one of the main
causes of fatigue in this discipline [1,5,6]. In addition, sustained and intense exercise may increase the
levels of circulating muscle damage markers, such as serum creatine kinase (CK), lactate dehydrogenase
(LDH) and myoglobin (Mb) as well as hormones, such as cortisol, which is involved in the activation
of catabolic processes and anti-anabolic actions related to protein turnover [7]. These parameters
are indicative of increased muscle damage and oxidative stress, which negatively affect athletes’
performance and increase the duration required for optimal recovery [4,8–10]. As a result, athletes not
only may reduce their performance, but also may put their health at risk.
Oral iron supplementation is an effective nutritional strategy that may be considered for
individuals with suboptimal FER levels and for preventing iron deficiency [11]. In addition to an
adequate iron intake from the regular diet, iron supplementation (~80 mg/day) can be considered to
prevent decreases in iron levels and related parameters in athletes undergoing a high level of effort [12].
This supplementation has shown improvements in FER and the hematological profile during training
periods in different sports [11–14]. It is well-known that endurance stage races, such as the Tour de
France [5] or the Giro d’Italia [1] reduce hematological parameters. However, to our knowledge, iron
supplementation has not been tested during a 3-week cycling race.
Recent studies have determined a relationship between skeletal muscle and body iron
metabolism [15]. In fact, increased iron availability triggered by low hepcidin levels may provide
iron levels that contribute to muscle growth [15]. However, no authors have demonstrated
iron supplementation to be a successful nutritional strategy to reduce muscle damage and stress.
We hypothesize that oral iron supplementation will be a useful ergogenic aid to improve hematological
profiles and reduce muscle damage and stress in non-anemic athletes.
The aim of this study was to evaluate the effects of 80 mg/day of oral iron supplementation
(800 mg of iron protein succinylate) on the hematological profile (sFe, FER, transferrin saturation index
(TSI), hematocrit (Htc), and Hb), muscle damage intracellular enzymes (CK, LDH, Mb) and cortisol
in elite male cyclists over a time-span of 4 weeks during the Vuelta a España. Our secondary aim was
to examine the relationship between the hematological profile and biochemical muscular damage
parameters and cortisol. We hypothesize that iron supplementation will prevent any decline in the
hematological profile and subsequently, decrease muscle damage.
2. Materials and Methods
2.1. Sample
Eighteen professional male cyclists from two different elite teams participated in the study.
Both teams had similar objectives and competed in the 3-week cycling stage race known as the Vuelta a
España, which covers around 3300 km. Medical examinations were conducted by the Union Cyclist
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International (UCI) to ensure participants were free of disease prior to the beginning of the study.
To the authors’ knowledge, no banned drugs or medications were taken by the riders. None of the
athletes tested positive for the routine doping tests performed before and during the race according to
the World Anti-Doping Agency (WADA).
All participants had analogous dietetic and training programs to prepare the race and were
supervised by a team physician in collaboration with one of the authors of the study. Physiotherapeutic
and nutritional post-exercise recovery strategies were also pretty similar. All participants were
informed of the experimental procedures, risks and benefits and voluntarily signed a written consent.
The study was designed according to the Declaration of Helsinki for experiments with human beings
and was approved by the local Ethics Committee of University of Valladolid.
2.2. Experimental Protocol and Assessment Plan
A randomized and non-controlled by placebo design was applied to analyse the effects of oral
iron supplementation on the hematological profile, biomarkers of muscular damage and cortisol levels.
Participants were assigned to groups using a stratified block design. An independent
statistician generated the following random allocation sequence: (a) a control group (CG, n = 9,
age: 26.1 ± 4.6 years; maximum oxygen uptake per kg: 78.0 ± 5.4 mL/kg/min) that did not receive
oral iron, (b) group treated with 80 mg/day iron (ITG, n = 9, age: 25.7 ± 6.4 years; maximum oxygen
uptake per kg: 77.6 ± 6.5 mL/kg/min).
The cyclists were tested at two specific points during the study: at baseline one week before
the start of the race (T1) for diet/supplementation homogenization and at the beginning of the last
stage (T2) (3rd week of race). Therefore, the total time between T1 and T2 was 4 weeks, including
the first week being for homogenization and the remaining 3 weeks for the race. The ITG received
80 mg/day oral iron in the form of 800 mg of iron protein succinylate (Ferplex 40®, Italfarmaco S.A.,
Madrid, Spain). Iron supplementation was provided in doses of 40 mg twice per day according to the
laboratory´s instructions during breakfast and dinner in the 4-week period.
Protein succinylate was chosen in order to avoid problems related to tolerance, gastrointestinal
discomfort, bioavailability and food/supplement compatibility [16]. During the competition,
the research team ensured that constant circadian rhythms were maintained in terms of nutrition,
hydration, timing of food intake and sleep, which is a normal practice in cycling competitions.
2.3. Dietary Assessment
A professional dietitian strictly recorded the daily food and fluid intake of the cyclists during
the study. The EasyDiet© package, which is available online (https://www.easydiet.es/), was used
to calculate the nutrient composition and energy intake from the foods and drinks consumed by the
cyclists. This software package was developed by the Spanish Centre for Higher Studies in Nutrition
and Dietetics (CESNID) and is based on the Spanish tables of food composition [17]. In addition,
all participants received multivitamin pills that included folic acid (5 mg/day), vitamin C (1 g/day),
B12 vitamin (1000 µg/day), branched amino acids and glutamine.
2.4. Body Composition and Anthropometric Measures
Anthropometric measurements were taken by an ISAK (International Society for Advancement in
Kinanthropometry) level 3 anthropometric device, following the standard procedures in T1. The height
and body weight technical error of measurement was less than 0.02%, and it was less than 2.6% in the
case of skinfolds. The height (cm) was measured with a SECA© measuring rod (Barcelona, Spain),
with a precision of 1 mm (range: 130–210 cm), and body weight (kg) was assessed by a SECA© scale,
with a precision of 0.1 kg (range: 2–130 kg). All skinfolds (triceps, biceps, abdominal, supraspinal,
subscapular, chest, front thigh and medial calf) were taken using a Harpenden skinfold caliper (CMS
instruments, London, UK), with a precision of 0.2 mm. The sum of 6 skinfolds (triceps, abdominal,
supraspinal, subscapular, front thigh and medial calf) was calculated as a reference for fat content.
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2.5. Blood Collection and Analysis
Blood extraction and transportation were performed according the UCI and WADA guidelines
(www.ama-wada.org). All samples were collected under basal conditions after a 10–12 h overnight
fast at T1 and T2. The blood samples (15 mL) were obtained at 8:30 a.m. from the antecubital vein
with the subject seated in a comfortable position using Vacutainer tubes. Blood was distributed in one
tube with gel and clot activator (10 mL) to obtain serum, and other EDTA tubes (3–5 mL) were used to
obtain plasma.
Immediately after filling, EDTA tubes containing blood were inverted 10 times and stored in a
sealed box at 4 ◦C. Temperature control was assured during transportation; the specific tag Libero
Ti1-Elpro (Buchs, Switzerland) was used for temperature measurement and recording. The EDTA
anticoagulated blood was processed according to UCI and WADA recommendations [18]. Blood in
EDTA tubes was centrifuged at 2000 rpm for 15 min. Plasma (upper layer) was extracted using a
Pasteur pipette, transferred to a sterile tube and stored at −20 ◦C until the moment of analysis.
Red blood cells (RBC), Hb and Hct were determined in the Hematology Analyser Sysmex XE-2100
(Barcelona, Spain).
Serum from blood samples was separated by low-speed centrifugation and analysed according
to Wilkinson et al. [19]. Total serum protein was determined by a colorimetric method using an
autoanalyser Hitachi 917 (Tokyo, Japan). Serum Fe and total iron-binding capacity were measured in
an automated chemistry analyser Synchron CX (Beckman Coulter Diagnosis, Madrid, Spain). FER was
determined in duplicate using the IRMA kit (Bio-Rad, Madrid, Spain). Transferrin (TRF) was measured
by nephelometry (Boehringer–Mannheim, Barcelona, Spain). Finally, the transferrin saturation index
(TSI) (%) was calculated as the ratio of sFe to the total iron binding capacity.
Serum levels of CK and LDH were measured using coupled enzyme reactions on an automatic
autoanalyser Hitachi 917. Mb assessment was performed using a chemiluminescence immunoassay.
Cortisol levels were measured by an enzyme-linked fluorescent assay in a multiparametric analyser
Minividas® (Biomerieux, Marcy l’Etoile, France) using 4 methyl umbelipherone as a substrate with
stimulation at 370 nm and emission at 450 nm.
2.6. Statistical Data Analyses
Statistical analyses were performed using the using SPSS Statistics software (SPSS: An IBM
Company, version 24.0, IBM Corporation, Armonk, NY, USA) and Graphpad Prism (Graphpad
Software version 6, San Diego, CA, USA). Data were expressed as mean ± standard (SD) deviation.
Significant differences were established at p < 0.05. Differences between groups for hematological
parameters, muscle damage and cortisol parameters were assessed by independent Student’s t tests
after normality had been confirmed with the Shapiro–Wilk test, opting for a parametric analysis.
Likewise, parametric paired t-tests were used with the blood sample parameters to identify significant
differences between T1 and T2 in each group independently. Additionally, a two-way repeated
measure analysis of variance (ANOVA) was carried out using the Greenhouse–Geisser test to confirm
the existence of an interaction effect (time × group) between CG and ITG for hematological parameters,
muscle damage and cortisol parameters throughout the study (T1 and T2). Effect sizes among
participants were calculated using partial eta square (η2p). Since this measure is likely to overestimate
effect sizes, values were interpreted in accordance with Ferguson [20], whereby no effect is indicated by
0 ≤ η2p < 0.05; a minimum effect is indicated if 0.05 ≤ η2p < 0.26; a moderate effect is indicated
if 0.26 ≤ η2p < 0.64; and a strong effect is indicated if η2p ≥ 0.64. Lastly, correlations between
hematological parameters and muscular biomarkers were examined using Pearson´s correlation
coefficient in order to estimate the association between two variables.
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3. Results
Table 1 depicts the anthropometric and physiological characteristics of the participants at T1.
No significant differences between groups were found (p > 0.05).
The average daily energy and micronutrient intake in CG and ITG during the 4 weeks of study
can be observed in Table 2. No significant differences between groups for total caloric intake and
micronutrients, including iron, were found (p > 0.05).
Table 1. Physical and anthropometric characteristics in the control group (CG) and iron treatment
group (ITG) at baseline (T1).
CG ITG p
Age (years) 26.1 ± 4.6 25.7 ± 6.4 0.880
Weight (kg) 69.3 ± 5.6 69.9 ± 7.9 0.854
Height (cm) 179.1 ± 12.8 178.2 ± 16.3 0.898
Σ 6 skinfolds (mm) 35.2 ± 7.5 35.4 ± 8.2 0.956
Maximum oxygen uptake (mL/kg/min) 78.0 ± 5.4 77.6 ± 6.5 0.889
Data are expressed as mean ± standard deviation. p: Differences between groups as determined by independent
t-tests (CG vs. ITG).
Table 2. Average daily energy and micronutrient intakes in the control group (CG) and iron treatment
group (ITG) during the 4 weeks of study.
GC ITG p
Energy (kcal/kg) 76.4 ± 5.8 75.4 ± 4.7 0.693
Calcium (mg) 2153 ± 222 2336 ± 257 0.126
Magnesium (mg) 1030 ± 109 1042 ± 72 0.786
Phosphorus (mg) 3928 ± 84 4032 ± 291 0.318
Iron (mg) 43.2 ± 5.6 43.7 ± 4.0 0.830
Zinc (mg) 26.5 ± 0.8 27.0 ± 2.2 0.531
Vitamin A (µg) 3512 ± 1270 3186 ± 585 0.494
Vitamin E (mg) 32.4 ± 3.5 30.6 ± 2.9 0.252
Thiamine (mg) 4.86 ± 0.20 4.64 ± 0.54 0.269
Riboflavin (mg) 5.08 ± 0.22 5.31 ± 0.54 0.254
Niacin (mg) 70.2 ± 6.8 69.1 ± 7.3 0.745
Vitamin B6 (mg) 7.18 ± 0.62 7.04 ± 0.97 0.720
Folic Acid (µg) 1177 ± 176 1175 ± 158 0.980
Vitamin B12(µg) 17.62 ± 3.89 16.61 ± 4.38 0.611
Vitamin C (mg) 650 ± 148 702 ± 158 0.482
Data expressed as mean ± standard deviation. p: Differences between groups as determined by independent t-tests
(CG vs. ITG).
Table 3 shows the mean ± SD of certain hematological parameters directly or indirectly related to
iron homeostasis. These include TRF, TSI, total serum proteins and RBC in CG and ITG at T1 and T2.
Statistically significant differences in the group-by-time interaction of TSI (p = 0.025; η2p = 0.248), TP
(p = 0.017; η2p = 0.290), and RBC (p < 0.001; η2p = 0.815) between the two groups through the study
were observed in favour of ITG. Along this line, ITG presented significant increases between T1 and
T2 (p < 0.05) in TSI (T1: 35.5 ± 10.0 vs. T2: 31.1 ± 12.9%), TP (T1: 6.9 ± 0.3 vs. T2: 7.1 ± 0.3 g/L) and
RBC (T1: 4.8 ± 0.3 vs. T2: 5.3 ± 0.2 × 106/µL). However, CG did not present significant differences
between T1 and T2 for any hematological parameters (p > 0.05).
Figure 1 displays the mean ± SD of other hematological parameters that are related to iron
homeostasis. These include sFe, FER, Hb and Hct in CG and ITG at T1 and T2. The results show
statistical differences in the group-by-time interaction for sFe (p = 0.018; η2p = 0.271), FER (p = 0.004;
η2p = 0.395), Hb (p < 0.001; η2p = 0.723) and Hct (p < 0.001; η2p = 0.586) in favor of ITG. As a result,
significant increases were observed in ITG with respect to CG at T2 (sFe: CG: 98.9 ± 15.8 vs. ITG:
116.7 ± 14.4 µg/dL; FER: CG: 104.7 ± 41.2 vs. ITG: 231.0 ± 62.0 ng/mL; Hb: CG: 15.0 ± 1.2 vs. ITG:
Nutrients 2019, 11, 500 6 of 13
16.6 ± 0.5 g/L; Hct: CG: 44.1 ± 3.0 vs. ITG: 49.7 ± 2.0 %; all p < 0.05). The absence of significant
differences at T1 reinforces the homogeneity of the participants at the beginning of intervention T2 (sFe:
CG: 108.6 ± 39.6 vs. ITG: 116.0 ± 21.6 µg/dL; FER: CG: 128.3 ± 55.7 vs. ITG: 153.3 ± 68.8 ng/mL; Hb:
CG: 15.1 ± 0.8 vs. ITG: 14.7 ± 0.9 g/L; Hct: CG: 44.6 ± 2.5 vs. ITG: 46.3 ± 2.6%; all p > 0.05). On the
other hand, while CG only presented significant differences in FER between T1 and T2 (p < 0.05), ITG
presented significant increase (p < 0.05) in FER, Hb and Hct.
Table 3. Hematological parameters and total protein in the control group (CG) and iron treatment
group (ITG) at baseline (T1) and after 3 weeks (T2).
Group T1 T2 p η2p
Transferrin (mg/dL)
CG 243.3 ± 25.4 234.4 ± 24.2
0.195 0.097ITG 232.0 ± 18.6 242.3 ± 44.4
Transferrin Saturation Index (%)
CG 31.7 ± 9.6 29.9 ± 8.9
0.025 0.248ITG 35.5 ± 10.0 31.1 ± 12.9 &
Total Protein (g/dL)
CG 7.0 ± 0.3 7.0 ± 0.6
0.017 0.290ITG 6.9 ± 0.3 7.1 ± 0.3 &
Red Blood Cells (×106 cells/µL)
CG 4.9 ± 0.4 4.9 ± 0.4
<0.001 0.815ITG 4.8 ± 0.3 5.0 ± 0.2 &
Data are expressed as mean ± standard deviation. p: group-by-time interaction (p < 0.05, all such occurrences).
Two-factor repeated-measures ANOVA. No significant differences between groups (CG vs. ITG) were found by
independent t-tests. & Significant differences (p < 0.05) over time (T1 vs. T2) within the same group as determined
by dependent t-tests.
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Figure 2 depicts the mean ± SD of circulating muscle damage markers (CK, LDH and Mb) and 
cortisol, which is considered to be a stress marker, during T1 and T2 in CG and ITG. Regarding 
Figure 1. Concentrations of (a) serum iron (sFe), (b) ferritin (FER), (c) hemoglobin (Hb) and
(d) hematoc it (Hct) in the control group (CG) and iron tr atment group (ITG) at baseline (T1) and after
3 weeks (T2). Data are expressed as mean ± standard deviation. p: group-by-time interaction (p < 0.05,
all such occurrences). Two-factor repeated-measures ANOVA. &: Significant difference between phases
as determined by dependent t-tests (T1 vs. T2), p < 0.05. *: Significantly different between groups as
determined by independent t-tests (CG vs. ITG), p < 0.05.
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Figure 2 depicts the mean ± SD of circulating muscle damage markers (CK, LDH and Mb) and
cortisol, which is considered to be a stress marker, during T1 and T2 in CG and ITG. Regarding muscle
markers, there were no significant differences in the group-by-time interaction between the two groups
through the study (T1 vs. T2). However, when comparing within groups, CK decreased in the ITG
at the end of the intervention period (T1: 306.7 ± 56.12 UI/L vs. T2: 260.8 ± 66.3 UI/L; p < 0.05).
LDH (T1: 378.3 ± 112.2 vs. T2: 296.6 ± 89.6 UI/L), and to a lesser degree Mb (T1: 23.3 ± 6.3 vs. T2:
24.2 ± 5.8 ng/mL) presented a tendency to decrease in ITG at T2, although the differences were not
significant (p > 0.05). No changes were noticed for CK, LDH and Mb in the CG when comparing
T1 vs. T2.
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negative correlation with C (r = −0.596; p = 0.011). In the same way, there were higher negative 
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Figure 2. Concentrations of (a) creatine kinase (CK), (b) lactate dehydrogenase (LDH), (c) myoglobin
(Mb) and (d) cortisol (C) in the control group (CG) and in the iron treated group (ITG) at the
beginning (T1) and at the end of intervention (T2). Data are expressed as mean ± standard deviation.
P: group-by-time interaction (p < 0.05, all such occurrences). Two-factor repeated-measures ANOVA.
&: Significantly different between phases as determined by dependent t-test (T1 vs. T2), p < 0.05.
Regarding cortisol, there were significant differences in the group-by-time interaction between
the two groups throughout the study (T1 vs. T2) (p = 0.005; η2p = 0.495). Concretely, this parameter
significantly increased only in the CG at the end of the intervention period (T1: 15.4 ± 3.2 vs. T2:
19.3 ± 6.1 mg/dL). However, in ITG, there was a tendency for circulating cortisol to decrease, although
the difference between T1 and T2 was not significant (T1: 16.2 ± 5.9 mg/dL vs. T2: 15.1 ± 2.3 mg/dL;
p > 0.05).
Co relations between hem tologi al par m ters related to iron homeostasis and biochemical
muscle markers are shown in Table 4. High negative correlations were observed for sFe with LDH (r =
−0.944; p < 0.001), Mb (r = −0.924; p < 0.001), and CK (r = −0.915; p < 0.001), and there was a moderate
negative correlation with C (r = −0.596; p = 0.011). In the same way, there were higher negative
correlations between Hb and all muscular markers: LDH (r = −0.986; p < 0.001), Mb (r = −0.994;
p < 0.001), CK (r = −0.996; p < 0.001). Moreover, Hb showed a higher negative correlation with
hormone C (r = −0.910; p < 0.001). Finally, FER also showed moderate-high negative correlations with
LDH (r = −0.643; p = 0.003), Mb (r = −0.0643; p = 0.003) and CK (r = −0.701; p = 0.001) and a high
negative correlation with C (r = −0.962; p > 0.001).
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Table 4. Correlations between hematological biomarkers (serum iron (sFe), hemoglobin (Hb) and
ferritin (FER)) and muscular biochemical markers (lactate dehydrogenase (LDH), myoglobin (Mb),
creatine kinase (CK) and cortisol (C)).
sFe Hb FER
LDH −0.944 ** −0.986 ** −0.643 *
Mb −0.924 ** −0.994 ** −0.643 *
CK −0.915 ** −0.996 ** −0.701 *
C −0.596 * −0.910 ** −0.962 **
Data are expressed by Pearson´s coefficient. * p < 0.005. ** p < 0.001.
Lastly, Figure 3 displays changes at the end of the study (T2–T1) in terms of the percentage of all
parameters analysed in Figures 1 and 2. A positive value indicates that the value of the parameter at
the end (T2) is higher than at the beginning (T1), and vice versa. Regarding hematological parameters,
there were significantly greater increases (p < 0.05) in favour of ITG compared to CG for sFe (CG:
−8.93 ± 10.35% vs. ITG: 0.60 ± 8.64%), Hb (CG: −0.41 ± 3.32% vs. ITG: 130.4 ± 5.64%), Hct (CG:
−1.17 ± 3.78 vs. ITG: 7.32 ± 3.92%) and FER (CG: −13.88 ± 23.53% vs. ITG: 91.08 ± 118.3%). On the
contrary, the percentage changes for muscle damage proteins such as CK (CG: 28.27 ± 100.25% vs. ITG:
−53.53 ± 29.18%) and Mb (CG: 3.86 ± 7.94% vs. ITG: −4.15 ± 8.15%) and cortisol (CG: 24.74 ± 25.84%
vs. ITG: −13.54 ± 13.61%) were significantly greater increases (p < 0.05) for CG compared with ITG.
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4. Discussion
To our knowledge, this is the first study to describe the effects of iron supplementation on the
modulation of iron-related metabolic para t rs, circulating muscle biomarkers and c rtisol in a
population of elit cyclists during a large co e race such as the Vuelta a España. The main
findings of the study were that sup lementation it 0 g/day iron significantly increas s sFe, FER,
Hb and Hct without changes in muscle bio arkers. Cortisol tended to decrease in the ITG, while
it significantly increased in the CG at the end of the race, indicating a higher level of effort-induced
stress. A significant negative correlation was observed for LDH, Mb and CK with sFe and Hb.
During the 3-week long stage competition, the metabolic homeostasis of the athletes suffered
a large amount of stress. Particularly, hematological parameters were modified due to the effort,
and consequently, by the adaptations required for the highly demanding performances [5,21].
Along this line, Mørkeberg et al. [5] and Corsetti et al. [1] reported significant decreases in Hb
and Hct during the Tour de France and Giro d´Italia, respectively, but no data regarding the use of
supplementation to correct these problems was reported. In our study, we did not find any significant
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differences in sFe, Hb and Hct in the CG between T1 and T2; however, we observed a decreasing
tendency for all haematological parameters. To avoid this situation, a recent review suggests that iron
supplementation may be useful to prevent iron deficiency in ultra-endurance athletes [22]. Likewise,
iron supplementation could prevent fatigue in subjects with iron depletion without anaemia [23], even
when the athletes take adequate amounts of iron in the diet [12]. We supplemented cyclists with
40 mg twice per day because previous studies [23] have demonstrated that doses higher than 60 mg of
iron increase hepcidin levels and consequently, decrease iron absorption. We also decided to use iron
proteinsuccinylate (Ferplex 40®) because it enhances iron bioavailability by up to 35% and reduces
the gastrointestinal problems and discomfort that are generally associated with intake of other iron
supplements [24,25]. Altogether, the results seem to support the recommendations made by other
authors, indicating that supplementation with 80 mg/day iron (800 mg of iron protein succinylate)
could not only prevent a decline but could also improve hematological parameters, including both Htc
and Hb, during 3-week long stage race such as the Vuelta a España.
Cumulative fatigue as a consequence of bouts of sustained and intense exercise compromises
muscle integrity, favouring the release of muscle-damage proteins, such as CK, Mb and LDH, to the
bloodstream. These proteins are regularly used as markers of muscle stress due to vigorously intense
exercise [4]. Similarly, although professional cyclists generally have higher LDH and CK values at
rest compared to sedentary individuals [26], these parameters were shown to further increase after
2 weeks of intense training [27]. This observation indicates that muscle integrity, and thereby function,
could be strongly compromised under prolonged, highly intensive exercise, such as in large cycling
competitions. Therefore, to maintain the cyclists’ health, it is important to preserve muscle integrity
as much as possible. It was observed that muscle integrity seemed to be preserved under more
optimal conditions in the ITG. However, the CG showed an increasing tendency for muscular damage
parameters to be present, consistent with previous studies [4,8–10]. In fact, circulating CK levels in the
ITG were significantly lower at the end of the race (T2) than at the beginning (T1). The other muscle
markers (LDH and Mb) also presented this tendency, but the differences between T1 and T2 were not
significant. This could be explained by the different half-lives that released muscle proteins have in
circulation: 1–1.5 days for CK and 6–7 days for LDH and Mb [28]. However, the differences observed
in these circulating parameters when comparing both groups (CG vs. ITG) were not significant,
suggesting that iron supplementation could help to prevent muscle damage, although it is likely that
other complementary strategies need to be considered to preserve muscle integrity during highly
demanding efforts. Other studies have corroborated the benefits of iron supplementation. For example,
Dely et al. indicated lower CK values in both adults and children after aseptic skeletal muscle trauma
when they were supplemented with iron [29]. Other studies, such as that of Dallman et al., which was
performed in rats, showed a normalization of Mb levels when sFe deficiency was corrected through
iron supplementation [30]. Altogether, these results reinforce the idea that iron supplementation
could avoid, or at least ameliorate, muscle damage. However, future studies are necessary to adapt
these recovery strategies to the particular situation that occurs in demanding sport disciplines such as
endurance cycling competitions.
Although the molecular mechanisms have not been addressed in the present study, it is evident
that there is a correlation between adequate iron homeostasis and optimal muscle function [15].
This is manifested by the need for oxygen delivery to the working muscles as well as mitochondrial
energy production through Hb and Mb. Therefore, it is evident that an optimal iron balance is
instrumental for the majority of the physiological variables involved in athletic performance [31].
Moreover, iron metabolism is also instrumental in post-exercise recovery periods. In this context,
a more adequate recovery may lead to a greater training volume and skeletal muscle adaptations,
and iron supplementation strategies could also accelerate the recovery time between sessions [12].
Consistently, a previous study described decreases in sFe, Hb and Hct levels together with a significant
increase in the circulating muscle biomarkers CK and LDH in elite athletes after an ultra-marathon
competition [32]. These results were very similar to the observations reported in the present study.
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In addition, the correlations calculated could illustrate this connection between muscle integrity and
iron metabolism [15]. Therefore, iron supplementation could be a good strategy to increase iron stores
and enhance endurance capacity by means of improving hematological parameters and therefore
decreasing fatigue and muscle damage [15]. In any case, in order to optimize performance and
recovery in disciplines that require very intensive physical effort, future research needs to decipher the
molecular mechanisms involved [33].
Serum cortisol levels are considered to be an indicative factor of accumulated stress in response
to intensity [8,34]. The level of response is modulated by both the relative intensity and duration of the
exercise [35]—higher intensity and longer duration correspond to greater cortisol release. Moreover,
it has been indicated that when the relationship training/recovery is well graduated, cortisol levels
return to basal levels within 24 h post-exercise [10,34,36]. Similarly, Hough et al. observed higher
cortisol values after 11 days of a highly intense cycling training period, indicating high levels of
stress and inadequate recovery [37]. In the present study, we observed a significant increase in basal
serum cortisol in CG, but not in ITG after 3 weeks of racing, indicating a lower level of stress and,
most likely, better recovery in ITG. In another study, Clemente showed a decrease in cortisol and
hematological parameters 5 days after an ultra-endurance race [35]. Therefore, low cortisol levels seem
to be necessary to modulate the exercise-induced inflammatory response [38] that is instrumental for
muscle repair/regeneration and optimal recovery to allow better future performances [39].
Our study has some limitations. First, we did not record the total time taken by the cyclists to
complete the Vuelta a España. Consequently, we were not able to relate the hematological and muscle
damage values to their performance. However, the particular role of each cyclist in the team during
the race made it difficult to address this interesting point. In this context, a long tour involves a great
effort by all individuals of the team. Individual and collective objectives can modulate the effort of
each particular member to a greater or lesser extent, which is translated into different physiological
responses and thereby performances.
Other limitation of the study is that we did not determine the plasma level of hepcidin. Plasma
hepcidin is negatively correlated with iron bioavailability, and iron supplementation acutely increases
circulating plasma hepcidin [40]. However, recently, Ihibashi et al. [41] reported that the effect of
moderate iron supplementation on the hepcidin level during strenuous training remains unclear.
Along this line, however, our results showed a statistical difference in the group-by-time interaction
for sFe in favour of ITG, indicating that the influence of hepcidin could be low.
5. Conclusions
In summary, oral supplementation with 80 mg/day iron (800 mg of iron protein succinylate)
over a 4 week period (week before and 3 weeks during a big tour—Vuelta a España) was shown to
be sufficient to prevent a decline in hematological levels (ferritin, hemoglobin and hematocrit) and
to reduce accumulated stress in response to exercise intensity (cortisol). Although 80 mg/day iron
(800 mg of iron protein succinylate) over four weeks was not enough to show a higher group-by-time
interaction of muscle damage biomarkers, it was observed that hematological levels were associated
with muscle damage biomarkers.
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